Jude Brigitte, Wibaut Bénédicte, Depret Sandrine
Institut d'Hématologie Biologique et d'Hémobiologie-Transfusion, CHRU, 59037 Lille.
Ann Med Interne (Paris). 2003 Sep-Oct;154(5-6):361-5.
Pregnancy and puerperium are well-known risk factors for venous thromboembolism, but the actual incidence of the disease is low (about 1/1,500 pregnancies). Pregnancy-associated venous thromboembolism is rare, though it is still the second cause of maternal death in France. Several types of prophylaxis are available, mainly clinical vigilance and aggressive investigation of women with symptoms of venous thromboembolism, or antithrombotic prophylaxis. Given the low incidence of the pathology, it seems desirable to select high-risk groups of women for such strategies. The most studied and identified risk factors are prior episodes of venous thromboembolism and biological thrombophilias. Prophylaxis through low molecular weight heparin during pregnancy and the puerperium should be considered mainly in these two groups. Noteworthy, no prospective and randomized study is available, and treatment recommendations are grade C.
妊娠和产褥期是静脉血栓栓塞的众所周知的危险因素,但该疾病的实际发病率较低(约为每1500例妊娠中有1例)。妊娠相关静脉血栓栓塞虽不常见,但仍是法国孕产妇死亡的第二大原因。有几种预防方法,主要是临床监测以及对有静脉血栓栓塞症状的女性进行积极检查,或进行抗血栓预防。鉴于该疾病发病率较低,似乎有必要为这类策略选择高危女性群体。研究最多且已明确的危险因素是既往静脉血栓栓塞发作史和遗传性易栓症。在妊娠和产褥期主要应对这两类人群考虑采用低分子量肝素进行预防。值得注意的是,尚无前瞻性随机研究,治疗建议为C级。